JP2011527331A - ピペリジニルｇｐｃｒ作動薬 - Google Patents

ピペリジニルｇｐｃｒ作動薬 Download PDF

Info

Publication number
JP2011527331A
JP2011527331A JP2011517245A JP2011517245A JP2011527331A JP 2011527331 A JP2011527331 A JP 2011527331A JP 2011517245 A JP2011517245 A JP 2011517245A JP 2011517245 A JP2011517245 A JP 2011517245A JP 2011527331 A JP2011527331 A JP 2011527331A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
mmol
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011517245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527331A5 (enExample
Inventor
リサ・サラ・バートラム
マシュー・コリン・ソーア・ファイフ
レバティ・ペルペチュア・ジーヴァラトナム
ジョン・カイリー
トーマス・マルティン・クルレ
クリステル・マリー・ラサミソン
コリン・ピーター・サムブルック−スミス
サイモン・アンドリュー・スウェイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812646A external-priority patent/GB0812646D0/en
Priority claimed from GB0812622A external-priority patent/GB0812622D0/en
Priority claimed from GB0902391A external-priority patent/GB0902391D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2011527331A publication Critical patent/JP2011527331A/ja
Publication of JP2011527331A5 publication Critical patent/JP2011527331A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2011517245A 2008-07-10 2009-07-10 ピペリジニルｇｐｃｒ作動薬 Withdrawn JP2011527331A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0812646A GB0812646D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812622.9 2008-07-10
GB0812646.8 2008-07-10
GB0812622A GB0812622D0 (en) 2008-07-10 2008-07-10 Compounds
GB0902391.2 2009-02-13
GB0902391A GB0902391D0 (en) 2009-02-13 2009-02-13 Compounds
PCT/GB2009/050825 WO2010004343A1 (en) 2008-07-10 2009-07-10 Piperidinyl gpcr agonists

Publications (2)

Publication Number Publication Date
JP2011527331A true JP2011527331A (ja) 2011-10-27
JP2011527331A5 JP2011527331A5 (enExample) 2012-08-16

Family

ID=41070447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517245A Withdrawn JP2011527331A (ja) 2008-07-10 2009-07-10 ピペリジニルｇｐｃｒ作動薬

Country Status (15)

Country Link
US (1) US20110269734A1 (enExample)
EP (1) EP2321297A1 (enExample)
JP (1) JP2011527331A (enExample)
KR (1) KR20110036609A (enExample)
CN (1) CN102083813A (enExample)
AU (1) AU2009269772A1 (enExample)
CA (1) CA2728042A1 (enExample)
CL (1) CL2011000051A1 (enExample)
EA (1) EA201170151A1 (enExample)
IL (1) IL209978A0 (enExample)
MA (1) MA32467B1 (enExample)
MX (1) MX2011000060A (enExample)
PE (1) PE20110329A1 (enExample)
WO (1) WO2010004343A1 (enExample)
ZA (1) ZA201008955B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013048916A1 (en) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
CA2855009C (en) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
WO2018068295A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
AU2022279234B2 (en) 2021-05-21 2025-08-28 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
JP7723119B2 (ja) 2021-05-21 2025-08-13 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス感染症の治療のための四環系化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) * 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト

Also Published As

Publication number Publication date
MX2011000060A (es) 2011-02-22
EP2321297A1 (en) 2011-05-18
WO2010004343A1 (en) 2010-01-14
KR20110036609A (ko) 2011-04-07
IL209978A0 (en) 2011-02-28
CN102083813A (zh) 2011-06-01
EA201170151A1 (ru) 2011-08-30
AU2009269772A1 (en) 2010-01-14
MA32467B1 (fr) 2011-07-03
CA2728042A1 (en) 2010-01-14
PE20110329A1 (es) 2011-06-03
ZA201008955B (en) 2011-08-31
US20110269734A1 (en) 2011-11-03
CL2011000051A1 (es) 2012-03-16

Similar Documents

Publication Publication Date Title
JP2011527332A (ja) ピペリジンｇｐｃｒ作動薬
JP4916452B2 (ja) Ｇｐｃｒ作動薬としてのピリジン、ピリミジン、およびピラジンの誘導体
US20110269734A1 (en) Piperidinyl gpcr agonists
EP2114935B1 (en) Piperidine gpcr agonists
JP2011527334A (ja) ヘテロ環式ｇｐｃｒ作動薬
EP2318399B1 (en) Piperidinyl gpcr agonists
JP2011500658A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP2010514829A (ja) ピペリジンｇｐｃｒアゴニスト
JP2010514832A (ja) ピペリジンｇｐｃｒアゴニスト
JP2011527335A (ja) ヘテロ環式ｇｐｃｒ作動薬
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
JP2010514828A (ja) ピペリジンｇｐｃｒアゴニスト
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
JP2012211204A (ja) Ｇｐｃｒアゴニスト
JP2011500659A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
HK1158192B (en) Piperidine gpcr agonists
HK1135704B (en) Piperidine gpcr agonists
HK1157329B (en) Piperidinyl gpcr agonists
HK1135705B (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120629

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130329